ParcelBio

Winter 2024Active

Elevated mRNA for transformative medicines.

Save

ParcelBio

Winter 2024Active

Elevated mRNA for transformative medicines.

Save

Company details

ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics.

Location

San Francisco, CA, USA

Founded

Unknown

Request the ParcelBio report.

ParcelBio has no report yet. Sign in with your email to request one.